期刊文献+

NOD2信号增强对负载白血病抗原的树突状细胞的作用研究

Activation of NOD2 Signalling Pathway Stimulates the Function of Human Dendritic Cells Loaded with Leukemia Cell Lysates
在线阅读 下载PDF
导出
摘要 本研究旨在探讨胞壁酰二肽(muramyldipeptide,MDP)激活NOD2信号通路对白血病抗原致敏的树突状细胞(dendritic cells,DC)的免疫调控影响。采用梯度离心法获取健康人外周血单个核细胞(peripheral blood mononuclear cells,PBMNC),体外给予3种细胞因子诱导培养7 d,第5 d给予白血病细胞株HL-60冻融抗原致敏DC,DC诱导成熟后,给予MDP(2000 ng/ml,24 h)刺激各组细胞。应用RT-PCR和Western blot检测NOD2 mRNA和蛋白表达,流式细胞仪分析各组DC表面分子,ELISA法检测各组DC培养上清中IL-12和p40表达。结果显示:MDP作用于经不同方式处理的DC后,可以刺激NOD2 mRNA和蛋白的表达,并以负载白血病细胞株HL-60冻融抗原并给予MDP刺激DC组(致敏DC+MDP组)最高,其显著高于仅给予MDP刺激无负载抗原DC组(DC+MDP组)和无MDP刺激致敏DC组,差异有统计学意义(P<0.05);DC表面分子(HLA-DR、CD80、CD83、CD86、CD40)在致敏DC+MDP组表达明显高于DC+MDP组和致敏DC组,未处理DC表达最低,差异有统计学意义(P<0.05);同样地发现,致敏DC+MDP组分泌细胞因子IL-12 p40最高为(898.30±61.08)pg/ml,显著高于DC+MDP组(573.86±32.09)pg/ml和致敏DC组(365.03±28.86)pg/ml,差异有统计学意义(P<0.05)。结论:MDP可明显上调致敏DC中NOD2 mRNA和蛋白表达,同时促进致敏DC表面HLA-DR、协同共刺激分子、黏附分子表达及炎性因子IL-12和p40分泌。本研究有望为DC在白血病免疫治疗中的应用提供新思路。 The purpose of this study was to explore the effect of NOD2 signalling pathway activated by muramyl dipeptide (MDP) on the immunomodulation effect of human monocyte-derived dendritic cells (DC) loaded with leukemia cell lysates. Peripheral blood mononuclear cells (PBMNC) were isolated by density gradient centrifugation, These cells were cultured with three cytokines for 7 days to induce their maturation. On the 5th day, cells were loaded with leukemia cell HL-60 lysates. NOD2 expression was detected by RT-PCR and Western blot. The phenotype of DC were analyzed by flow cytometry, and ELISA was used to assay levels of IL-12 (p40) . The results showed that MDP could trigger NOD2 mRNA and protein expression in different groups of DC, especially in sensitized DC + MDP group, which was significantly higher than that in the DC + MDP group and sensitized DC without MDP stimulation, the difference was statistically significant ( P 〈 0.05 ). Besides, the expression of surface molecules ( HLA-DR, CD80, CD83, CD86, CD40) in the group of DC loaded with leukemia cell lysate and stimulated by MDP( sensitized DC + MDP) reached the highest level, followed by the group of DC loaded with leukemia cell lysate without MDP and DC only stimulated by MDP, non-treated DC were the lowest(P 〈 0.05). Similarly, compared with untreated unstimulated DC, after loading with HL-60 lysates or only stimulating with MDP, the secretion of IL-12p40 increased, but IL-12p40 level ( 573.86 ± 32.09 pg/ml) in DC + MDP group was higher than that in group of sensitized DC ( 365.03 ±28.86 pg/ml ) (P 〈 0.05 ), and it in sensitized DC + MDP group reached the highest (898.30 ± 61.08 ) pg/ml, compared to other groups ( P 〈 0.05 ). It is concluded that MDP can significantly enhance the NOD2 mRNA and protein expression in sensitized DC, promote the expression of HLA-DR, synergistic costimulatory molecules and adhesion molecules of DC,at the same time, MDP can increase secretion of inflammatory factors IL-12p40. This study will provide a new ideas for DC application in leukemia immunotherapy.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2013年第6期1591-1596,共6页 Journal of Experimental Hematology
基金 湖北省自然科学基金(编号2011CD012) 宜昌市科技项目(编号A11301-02)
关键词 白血病 胞壁酰二肽 NOD2 信号通路 leukemia muramyldipeptide NOD2 signalling pathway
作者简介 通讯作者:郭静明,教授,主任医师.E-mail:gjm425@163.com
  • 相关文献

参考文献16

  • 1Grimwade D, Hills RK. Independent prognostic factors for AML out-come. Hematology Am Soc Hematol Educ Program, 2009:385 -395.
  • 2van de Loosdrecht AA, van den Ancker W, Houtenbos \ ,et al. Den-dritic cell-based immunotherapy in myeloid leukaemia: translatingfundamental mechanisms into clinical applications. Handb Exp Phar-macol, 2009; (188) : 319 -348.
  • 3Williams A, Flavell RA, Eisenbarth SC. The role of NOD-like Re-ceptors in shaping adaptive immunity. Curr Opin Immunol, 2010 ;22(1):34 -40.
  • 4Zhang Y, Ma B, Zhou Y ,et al. Dendritic cells fused with allogeneicbreast cancer cell line induce tumor antigen-specific CTL responsesagainst autologous breast cancer cells. Breast Cancer Res Treat,2007;105(3) :277 -286.
  • 5Delirezh N, Moazzeni SM, Shokri F, et al. Autologous dendritic cellsloaded with apoptotic tumor cells induce T cell-mediated immune re-sponses against breast cancer in vitro. Cell Immunol, 2009 ;257 (1 -2) :23 -31.
  • 6Banz A, Cremel M, Rembert A, et al. In situ targeting of dendriticcells by antigen-loaded red blood cells : a novel approach to cancerimmunotherapy. Vaccine, 2010;28( 17) :2965 -2972.
  • 7Turkeri L, Onol FF, Ozyurek M. Tumor specific cytotoxicity and te-lomerase down-regulation in prostate cancer by autologous dendriticcells loaded with whole tumor cell antigens. Urol Oncol, 2010; 28(3):290 -295.
  • 8Yang DH, Park JS,Jin CJ, et al. The dysfunction and abnormal sig-naling pathway of dendritic cells loaded by tumor antigen can beovercome by neutralizing VEGF in multiple myeloma. Leuk Res,2009;33?5) :665 -670.
  • 9Nakamura I,Kanazawa M, Sato Y,et al. Clinical evaluation of den-dritic cells vaccination for advanced, cancer patients at FukushimaMedical University. Fukushima J Med Sci, 2012 ;58( 1) :40 -48.
  • 10Geddes K, Magalhaes JG, Girardin SE, et al. Unleashing the thera-peutic potential of NOD-like receptors. Nat Rev Drug Discov, 2009;8(6) :465 -479.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部